Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III Study for Advanced or Metastatic Soft Tissue Sarcoma (STS)
Shots:
- The P-III ANNOUNCE study involves assessing of Lartruvo + doxorubicin following lartruvo monothx vs doxorubicin + PBO following PBO monothx in patients with advanced or metastatic STS
- The study didn’t meet 1EP as OS showing no difference in survival rate with no safety signals observed; AEs (all grades; grade 3-4) fatigue (69%-9% vs 3% 69%); musculoskeletal pain (64%- 8% vs 25%- 2%); decreased appetite (31%- 2% vs 20%- 0%); lymphopenia (77%- 44% vs 73%- 37%); hypokalemia (21%- 8% vs 15%- 3%)
- Lartruvo (olaratumab) is a platelet-derived growth factor receptor alpha (PDGFR-α) mAb used for blocking PDGFR-α and prevents receptor activation- indicated for soft tissue sarcoma (STS) in combination with doxorubicin
Ref: Eli Lilly | Image: Eli Lilly
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com